Focal Healthcare Receives FDA 510(k) Clearance and Health Canada Approval for Fusion Bx™ 2.0
Fusion Bx™ 2.0 leverages MRI/Ultrasound fusion technology to provide targeted prostate biopsies TORONTO, CANADA – Focal Healthcare, an innovator of image-guided prostate cancer technology, announced it has received both FDA 510(k) clearance and Health Canada approval for its Fusion Bx™ 2.0 prostate biopsy solution. The Fusion Bx 2.0 is now available for sale in the United […]